… the pivotal phase 2 ALPHA3 trial (NCT06500273) in large … death.1 The clinical trial, which is evaluating the … to treatment arms receiving cema-cel and fludarabine/cyclophosphamide … After Patient Death in Lymphoma Trial. BioSpace. August 4, 2025 …

… -cel; Breyanzi) for the treatment of adult patients with relapsed … open-label, global, multicenter trial evaluated liso-cel in patients … 47;m2 per day and cyclophosphamide at 300 mg/m2 … S. Food and Drug Administration (FDA) in fifth cancer type for relapsed …

… made in consultation with the FDA, the study’s Data … across Allogene’s other trials.1 Prior Patient Death … study treatment and has the potential to accelerate trial enrollment … and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for …

… its actively enrolling clinical trials for its therapeutic … in redefining the autoimmune treatment landscape," Zachary Roberts … development and the chief medical officer at Allogene, … and cyclophosphamide (FC) lymphodepletion regimen in the ALPHA3 trial …

… consultation with the FDA. Moreover, the arm of the trial evaluating cema … infections have arisen in clinical trials initiated by Allogene Therapeutics—the … plus cyclophosphamide lymphodepletion in an outpatient setting will simplify study treatment and …

… trial of cemacabtagene ansegedleucel, an investigative CAR T therapy for the treatment … “rare” across Allogene’s trials, the biotech said, but “when present … only using fludarabine and cyclophosphamide (FC) as lymphodepletion treatments for patients receiving …

… a clinical-stage biotechnology company pioneering the development … selected standard fludarabine and cyclophosphamide (FC) as … S. Food and Drug Administration (FDA). The arm … quickly, simplify study treatment, accelerate trial enrollment, streamline …

… CLLS), a clinical-stage biotechnology company using its pioneering … the Food and Drug Administration (FDA) and the European Medicines Agency (EMA … selected standard fludarabine and cyclophosphamide (FC) as the … T-cells to treat cancer patients, and a platform …

…  « Société »), société de biotechnologie de stade clinique, qui utilise … Drug Administration (FDA) ainsi qu’avec l’Agence Européenne des Médicaments … associant la fludarabine et cyclophosphamide standard (FC) pour … patients atteints de cancer, et une plateforme …

… randomized, controlled, adaptive trial platform recruited participants … alone, or fludarabine-cyclophosphamide-rituximab. Treatment protocols included FCR … Leeds Cancer Research UK Clinical Trials Unit … England Journal of Medicine. LIMITATIONS: According …